With the further development of organoid research, cell cryopreservation technology has become an important part of the biomedical industry. Recently, a leading organoid company in Shanghai made a final decision to use winTop therapy® cell cryopreservation bags in the selection of cell cryopreservation products. The decision was based on four main considerations: cost reduction, realization of domestic substitution, product quality testing, and the final reason for the choice.
1. Cost Reduction: Optimizing Research Budgets
Cell cryopreservation bags are essential in the process of organoid research and cell therapy, and the high price of products of internationally recognized brands has been a major problem in cost management of biological enterprises. The organoid company found that the price of international famous brands is 30%-50% higher in the long-term procurement process, which not only increases the operation cost of the laboratory, but also limits the scale of cryopreservation experiments to a certain extent.
The launch of winTop therapy® cell cryopreservation bags provides a more cost-effective solution for enterprises. It is estimated that the unit purchase cost of winTop therapy® bags is about 35% lower than that of internationally renowned brands, which significantly reduces the consumption cost of enterprises under the premise of ensuring the same storage capacity and quality standards. In the long run, choosing winTop therapy® not only optimizes the procurement budget, but also allows the company to invest more funds in core R&D and equipment upgrading, resulting in stronger market competitiveness.
2. Domestic Substitution: Securing Supply Chains
Imported brands pose risks:
✓ Unstable lead times
✓ Tariff/logistics costs
✓ Limited customization
winTop therapy® addresses these with:
• Fully localized production
• Flexible customization (sizes/materials)
• Policy-aligned incentives
3. Quality Validation: Benchmarking Against Global Brands
